Despite a few reported clinical studies in CRC therapy, more extensive studies and investigations are necessary to prove an increased bioavailability via the encapsulation of gallic acid and quercetin into nanoformulation as compare to polyherbal extract. The complete mechanism as well as the interactions between these nanoformulation and cancer cells is still unknown. Future studies should focus on understanding the effects of polyherbal nanoformulation on colon and CRC cells through long term studies, as well as polyherbal nanoformulation interactions with both normal and cancer cells. These are essential for the development of a safer and more effective chemotherapeutic agent taken from bench to bedside.